These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 34011534)
1. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. Kobayashi T; Iwama S; Sugiyama D; Yasuda Y; Okuji T; Ito M; Ito S; Sugiyama M; Onoue T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Nishikawa H; Arima H J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011534 [TBL] [Abstract][Full Text] [Related]
2. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357 [TBL] [Abstract][Full Text] [Related]
3. HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency. Ono M; Fukuda I; Nagao M; Tomiyama K; Okazaki-Hada M; Shuto Y; Kobayashi S; Yamaguchi Y; Nagamine T; Nakajima Y; Inagaki-Tanimura K; Sugihara H Pituitary; 2022 Aug; 25(4):615-621. PubMed ID: 35653047 [TBL] [Abstract][Full Text] [Related]
4. HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis. Ono M; Nagao M; Takeuchi H; Fukunaga E; Nagamine T; Inagaki K; Fukuda I; Iwabu M Eur J Endocrinol; 2024 Jul; 191(1):9-16. PubMed ID: 38917237 [TBL] [Abstract][Full Text] [Related]
5. Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event. Sasaki E; Natori Y; Tokuda E; Kimura-Tsuchiya R; Suga J; Kanazawa K; Koguchi T; Kikuchi N; Okabe N; Murono S; Tachibana K; Soeda S; Shimabukuro M; Saji S Immunotherapy; 2024; 16(11):723-732. PubMed ID: 38889451 [TBL] [Abstract][Full Text] [Related]
6. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis. Yang L; Zhang Y; Chen X; Liu K; Zhou Y; Wang S Clin Endocrinol (Oxf); 2024 Aug; 101(2):130-139. PubMed ID: 38753540 [TBL] [Abstract][Full Text] [Related]
7. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047 [TBL] [Abstract][Full Text] [Related]
8. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Yano S; Ashida K; Sakamoto R; Sakaguchi C; Ogata M; Maruyama K; Sakamoto S; Ikeda M; Ohe K; Akasu S; Iwata S; Wada N; Matsuda Y; Nakanishi Y; Nomura M; Ogawa Y Eur J Cancer; 2020 May; 130():198-203. PubMed ID: 32229416 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study. Hara N; Suwanai H; Yakou F; Ishii K; Iwasaki H; Abe H; Shikuma J; Sakai H; Miwa T; Suzuki R Endocrine; 2023 Sep; 81(3):477-483. PubMed ID: 37178310 [TBL] [Abstract][Full Text] [Related]
10. Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands. Iwama S; Arima H Endocr J; 2020 Nov; 67(11):1077-1083. PubMed ID: 33055452 [TBL] [Abstract][Full Text] [Related]
11. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review. Wang F; Shi X; Yu X; Yang Y Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292 [TBL] [Abstract][Full Text] [Related]
14. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498 [TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774 [TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. Iwama S; Kobayashi T; Arima H Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588 [TBL] [Abstract][Full Text] [Related]
17. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162 [TBL] [Abstract][Full Text] [Related]
18. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Iglesias P; Sánchez JC; Díez JJ Pituitary; 2021 Aug; 24(4):630-643. PubMed ID: 33761049 [TBL] [Abstract][Full Text] [Related]
19. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center. Barlas T; Sutcuoglu O; Akdogan O; Balos Toruner F; Akturk M; Ozdemir N; Yazici O; Eroglu Altinova A Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39194584 [TBL] [Abstract][Full Text] [Related]
20. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies. Chen H; Zhang L; Zhao L; Li X BMC Endocr Disord; 2023 Jul; 23(1):139. PubMed ID: 37415148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]